04 July 2018


Crowne Plaza, Holliday Street, Birmingham City Centre, B1 1HH

Contact info 01143 270230

Target audience

This meeting is open to health professionals involved in the management and treatment of Parkinson’s


A meeting designed to advance scientific insights for specialists working within Parkinson’s disease. Learn about cutting edge Parkinson’s research from top national key opinion leaders.

This meeting is supported by Bial, there are no costs.

Course agenda

Webinar Live Stream

Unable to attend the meeting? If you are a AHP you are invited to join the day’s presentations by webinar and will have the opportunity to participate in the Q&A.


Dr Peter Fletcher (Academic Director, Parkinson’s Academy)

Peter FletcherDr Peter Fletcher is a Consultant Care of the Elderly Physician at Gloucestershire Hospitals NHS Foundation Trust. He specialises in movement disorders and shares service delivery with colleagues from nursing and the allied health profession in Care of the Elderly, Neurology and Old Age Psychiatry. He runs 4 clinics on 3 sites across a very rural county.
He is a founder member and Academic Director of the Parkinson’s Academy and has contributed to all MasterClasses from their inception in 2002 to date. He is past Chair of the British Geriatrics Society Movement Disorders Section, a Trustee of The Cure Parkinson’s Trust and the current President of the Cheltenham branch of Parkinson’s UK.
He is an Honorary Reader at the University of Bristol Medical School, has an MSc in medical education and examines for the University of Bristol MB ChB programme and for the Royal College of Physicians of London DGM and MRCP PACES examinations.

Prof Roger Barker

Roger Barker is the Professor of Clinical Neuroscience at the University of Cambridge and Consultant Neurologist at the Addenbrooke’s Hospital Cambridge. He is a guest professor at the University of Lund, Sweden and a PI in the MRC-Wellcome Trust Stem Cell Institute in Cambridge. For the last 25 years he has run research that seeks to better define the clinical heterogeneity of two common neurodegenerative disorders of the CNS- namely Parkinson’s (PD) and Huntington’s disease (HD). This has helped him define the best way by which to take new therapies into the clinic. In this respect he has been heavily involved in gene and cell based trials for patients with these conditions and currently co-ordinates an EU funded transplant programme using human fetal tissue for patients with PD, following on from an earlier MRC funded trial using similar tissue in HD. He is part of a global initiative (GFORCE-PD) that is seeking to take stem cells to trial in these disorders.

Prof K. Ray Chaudhuri

Professor K. Ray Chaudhuri is Professor of Neurology/Movement Disorders and Consultant Neurologist at King’s College Hospital and King’s College London, an Academic Health Sciences Centre. He is Principal Investigator at the Maurice Wohl Clinical Neuroscience Institute at King’s College, London and NIHR biomedical research centre at the Institute of Psychiatry. He is also the medical director of the National Parkinson Foundation International Centre of Excellence at King’s College, London.
Professor Chaudhuri sits on the Nervous Systems Committee of the UK Department of Health, National Institute of Health Research, and has served as chairman (and now co-chairman) of the appointments/liaison committee of the Movement Disorders Society (2009–2013). He has served as a member of the scientific programme committee of the MDS (2013–2017) and is chairman of the MDS Non-Motor Study Group. He also serves on the task force of the practice parameter group for Parkinson’s disease (PD) and restless legs syndrome (RLS), evidence-based medicine for non-motor symptoms of PD and, more recently, non-motor symptoms of Parkinson’s, American Academy of Neurology.

Dr Donald Grosset

Donald Grosset is a Consultant Neurologist at the Institute of Neurological Sciences, Glasgow, and Honorary Professor at the University of Glasgow. His neurology interests began with his BSc degree (1st Class, 1983) and continued through to the award of his higher medical degree (1992).
He chaired the Scottish Intercollegiate Guidelines Network for Parkinson’s disease, and the Parkinson’s subgroup for Health Improvement Scotland, and the West Scotland group of UK Parkinson’s Excellence Network, before becoming Clinical Director for the Network.
He has served on the Education Committee of the International Movement Disorder Society, is a former Treasurer to the BRING-MD (British and Irish Neurologists’ Group for Movement Disorders), and former Secretary and Treasurer to the Scottish Association of Neurological Sciences.
His clinical and research interests are in Parkinson’s disease and Movement Disorders. His prior work includes the development of FP-CIT SPECT imaging as a diagnostic test for Parkinson’s disease, in collaboration with GE Healthcare, culminating in this being the first licensed radio-pharmaceutical in Europe; observations on therapeutic adherence in Parkinson’s disease patients, which was recognised in a research award from the International Movement Disorder Society. Current research focuses on population studies in Parkinson’s, including risks of family inheritance of the condition. He is the Chief Investigator for the PRoBaND study, also known as Tracking Parkinson’s, which is hosted by Glasgow University, supported by Glasgow Biomedicine, and funded by Parkinson’s UK (9 years). This is the largest ever prospective multi-centre study of Parkinson’s disease, involving cohorts of recent onset and young onset cases, and their first degree relatives. More than 70 centres across the UK are involved, as well as laboratory and research collaboration in Cardiff, and statistical and epidemiological support in Bristol. There are major collaborative links with the Oxford Discovery project, and the Critical Path Parkinson’s consortium.

Dr Emily Henderson

Emily HendersonDr Emily Henderson is a Consultant Geriatrician and lead for Movement Disorders Research at the Royal United Hospitals Bath and a Honorary Consultant Senior Lecturer at the University of Bristol. She was awarded a fellowship from Parkinson’s UK and The Association of British Neurologists to undertake a PhD in preventing falls in Parkinson’s. The results of this phase II trial were published in Lancet Neurology in 2016. She is Lead for the South West Parkinson’s Excellence Network and Subspecialty Lead for Ageing and Parkinson’s disease in the West of England Clinical Research Network (CRN). Nationally, she is British Geriatric Society Movement Disorder Section (BGSMDS) Vice Chair, sits on the National Parkinson’s Disease Portfolio Development Group (PD-PDG) and is a Faculty member of the Parkinson’s Academy.

Prof Huw Morris

Huw Morris is Consultant Neurologist and Professor of Clinical Neuroscience at the Royal Free Hospital, National Hospital for Neurology and Neurosurgery and UCL Institute of Neurology. His main clinical and research interests are in Movement Disorders and Neurogenetics, particularly early onset, genetic and familial Parkinson’s disease and atypical Parkinsonian disorders such as Progressive Supranuclear Palsy, Cortico-basal degneration and Fronto-temporal dementia with Parkinsonism. His clinical and research training took place at the National Hospital, Queen Square, the Mayo Clinic and the Western Pacific island of Guam. He was Senior Lecturer and then Professor of Neurology and Neurogenetics at Cardiff University from 2003 to 2013. His research is funded by Parkinson’s UK, the Medical Research Council, the PSP Association and the Motor Neuron Disease Association. He is Chair of the Dendron Parkinson’s Disease Clinical Studies Group and the Clinical Research and Academic Committee of the Association of British Neurologists. He serves on the Research Advisory Panels of Parkinson’s UK, the Motor Neuron DIsease Association, Cure PSP and the Multiple System Atrophy trust. He also serves on the Honorary Medical Advisory Panel on Driving and Disorders of the Nervous System for Driver and Vehicle Licensing Authority.

Dr Daniel van Wamelen

Dr Daniel van Wamelen is a clinical research fellow at King’s College London and the National Parkinson Foundation International Centre of Excellence, King’s College, London. His research interest are the motor and non-motor aspects of movement disorders. In his research, the focus has been on understanding the functional anatomy of non-motor symptoms, such as sleep and autonomic dysfunction, in movement disorders using neuropathological methods and clinical (translational) research.
He graduated in Medicine at Leiden University (the Netherlands), obtained his PhD entitled ‘Hypothalamic pathology in Huntington’s Disease’ at the same university with a large part of the work carried out at the Netherlands Institute for Neuroscience in Amsterdam. He trained as a Neurologist at the Leiden University Medical Centre where he obtained his degree in 2016. Daniel is a member of the European Huntington’s Disease Network, the International Parkinson and Movement Disorder Society and an associate member of the European Academy for Neurology.

Dr Ben Wright

Dr Ben Wright is a Consultant Neurologist at Queen Elizabeth Hospital Birmingham. He has a specialist interest in Parkinson’s disease and dystonia. He runs clinics for deep brain stimulation, Levodopa-Carbidopa Intestinal gel, and botulinum toxin. He is Principal Investigator to several clinical trials.

Bial logo

This meeting is supported by Bial and delivered in association with the Parkinson’s Academy

Bial Prescribing information

Date of preparation: June 2018